{
    "nct_id": "NCT05574101",
    "official_title": "A Phase II, Multicenter, Single-Arm Clinical Trial of Radiotherapy and CeMiPlimAb: Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART",
    "inclusion_criteria": "* Biopsy proven cutaneous squamous cell carcinoma which is locally advanced\n\n  * Mixed histology tumors that are predominantly squamous cell carcinoma are eligible\n  * Locally advanced primary tumor is T3-T4 and/or N+ by AJCC and/or UICC 8th edition clinical criteria\n* T3-T4 primary tumor characteristics noted below:\n\n  * Non-eyelid tumor >4 cm in maximum dimension or with bone erosion or invasion, perineural invasion of nerve 0.1 mm or larger, or invasion beyond subcutaneous fat or >6 mm from granular layer of adjacent normal epidermis\n  * Eyelid tumor >2 cm or invading adjacent ocular, orbital or facial structures\n* ≥18 years old\n* Unresectable or medically inoperable according to local multidisciplinary consensus for reasons such as:\n\n  * Tumor or regional lymph node metastases that has recurred despite ≥2 prior surgical procedures, with another curative resection unlikely\n  * Tumor or nodal disease with significant local invasion that precludes complete resection\n  * Tumor or nodal disease in anatomically challenging area where surgery may result in significant disfigurement or dysfunction (amputation of nose, ear, eye, digit, limb, etc)\n  * Medical contraindication to surgery\n  * Patient refusal of surgery due to anticipate morbidity\n* ECOG ≤2\n* Adequate bone marrow and metabolic function (by blood tests)\n\n  * Total bilirubin ≤1.5 x upper limit of normal\n  * Aspirate aminotransferase (AST) ≤3 x upper limit of normal\n  * Alanine aminotransferase (ALT) ≤3 x upper limit of normal\n  * Alkaline phosphatase ≤2.5 x upper limit of normal\n  * Serum creatinine ≤1.5 x upper limit of normal or estimated creatinine clearance >30 mL/min according to Cockcroft-Gault formula\n  * Hemoglobin >9 g/dL\n  * Absolute neutrophil count ≥1.5 x10^9/L\n  * Platelet count ≥75 x10^9/L\n* Able to provide informed consent\n* Acceptable candidate for curative intent radiotherapy and Cemiplimab immunotherapy, in opinion of radiation and medical oncologist, respectively\n* Life expectancy >18 months\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Primary tumor originating on the mucosal (non-hair bearing) lip or nose, anogenital (penis, scrotum, vulva, perianal) area\n* Iatrogenic immunosuppression (>prednisone 10 mg/day or equivalent within 14 days of initiation of treatment)\n* Women of child bearing potential unwilling or unable to use effective contraception while receiving treatment with cemiplimab and for 4 months thereafter\n* Distant metastases\n* Clinically significant autoimmune disease that requires iatrogenic immunosuppression\n\n  o For example, severe rheumatoid arthritis requiring disease modifying antirheumatic drugs, such as methotrexate\n* Current or previous hematopoietic malignancy (leukemia, lymphoma)\n* Prior allogeneic transplant of solid organ or bone marrow\n* Concurrent malignancies with >10% risk of metastasis or death within 2 years\n* Prior aPD1 immunotherapy or PI3Kδ inhibitor use\n* Prior radiotherapy for the cutaneous squamous cell carcinoma requiring treatment\n* Other ongoing cancer therapy\n\n  o Adjuvant endocrine therapy is permitted for patients with prostate or breast cancer\n* Uncontrolled HIV or infectious hepatitis (viral load detectable in patient with known infection)\n* Pregnancy or breastfeeding\n* Comorbid or diagnostic abnormalities within the last year that would interfere with interpretation of study results",
    "miscellaneous_criteria": ""
}